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c.1954A>G (p.Arg652Gly) in ABCB4 gene (homozygous) and 
c.1331T>C (p.Val444Ala) in ABCB11 gene (heterozygous). In 
conclusion, we describe the unique case of an adult male 
with choledocholithiasis, hepatolithiasis, and persistent 
conjugated hyperbilirubinemia after retrieval of stones, ful-
filling the criteria for LPAC syndrome and with possible su-
perimposed drug-induced liver injury, in whom ABCB4 and 
ABCB11 mutations were found, both of which had not been 
previously described in association with LPAC.
© 2017 Sociedade Portuguesa de Gastrenterologia 
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Um caso complexo de colestase num doente com 
mutações dos genes ABCB4 e ABCB11
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Resumo
A síndrome low-phospholipid-associated cholelithiasis 
(LPAC) é uma forma de coledocolitíase sintomática que 
ocorre em adultos jovens e que se caracteriza pela recor-
Keywords
Low-phospholipid-associated cholelithiasis · MDR3 · BSEP · 
Drug-induced liver injury 
Abstract
The low-phospholipid-associated cholelithiasis (LPAC) syn-
drome is a form of symptomatic cholelithiasis occurring in 
young adults, characterized by recurrence of symptoms af-
ter cholecystectomy and presence of hepatolithiasis. The 
case refers to a healthy 39-year-old Caucasian male who pre-
sented with abdominal pain and jaundice. His blood tests 
showed conjugated hyperbilirubinemia and elevated liver 
enzymes (total bilirubin 6.65 mg/dL, γ-glutamyltransferase 
699 IU/L) and abdominal computed tomography revealed 
dilation of common bile duct and left intrahepatic ducts. 
Magnetic resonance cholangiopancreatography identified 
choledocholithiasis, retrieved by endoscopic retrograde 
cholangiopancreatography, after which there was a worsen-
ing of jaundice (total bilirubin 23 mg/dL), which persisted for 
several weeks, possibly due to ciprofloxacin toxicity. After an 
extensive workup including liver biopsy, the identification of 
two foci of hepatolithiasis on reevaluation abdominal ultra-
sound raised the hypothesis of LPAC syndrome and the pa-
tient was started on ursodeoxycholic acid, with remarkable 
improvement. Genetic testing identified the mutation 
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rência de sintomas após a colecistectomia e pela presen-
ça de hepatolitíase. O caso refere-se a um homem cauca-
siano de 39 anos, saudável, que se apresentou com um 
quadro de dor abdominal e icterícia. A avaliação laborato-
rial mostrou hiperbilirrubinémia conjugada e um padrão 
citocolestático (bilirrubina total 6,65 mg/dL; GGT 699 
UI/L) e a tomografia computorizada abdominal revelou 
dilatação da via biliar principal e vias biliares intra-hepáti-
cas à esquerda. A colangiopancreatografia por ressonân-
cia magnética identificou coledocolitíase, extraída por co-
langiopancreatografia retrógrada endoscópica, tendo-se 
verificado posterior agravamento da icterícia (bilirrubina 
total 23 mg/dL) que persistiu por várias semanas, possi-
velmente por hepatotoxicidade associada à toma de ci-
profloxacina. Após uma extensa investigação, incluindo a 
realização de biópsia hepática, foram identificados dois 
focos de hepatolitíase em ecografia abdominal de reava-
liação, pelo que se colocou a hipótese de LPAC e o doente 
iniciou terapêutica com ácido ursodesoxicólico, com ex-
celente resposta. O estudo genético identificou a muta-
ção c.1954A>G (p.Arg652Gli) no gene ABCB4 em homo-
zigotia e a mutação c.1331T>C (p.Val444Ala) no gene 
ABCB11 em heterozigotia. Em suma, descrevemos o caso 
único de um homem com coledocolitíase, hepatolitíase e 
hiperbilirribinémia conjugada persistente mesmo após 
extracção de cálculos, cumprindo critérios de LPAC e pos-
sivelmente com sobreposição de lesão hepática induzida 
por fármacos, tendo-se documentado mutações nos ge-
nes ABCB4 e ABCB11, cuja associação com LPAC não havia 
sido previamente descrita.
© 2017 Sociedade Portuguesa de Gastrenterologia 
Publicado por S. Karger AG, Basel
Introduction
The low-phospholipid-associated cholelithiasis 
(LPAC) syndrome is a peculiar form of symptomatic and 
recurring cholelithiasis occurring in young adults, associ-
ated with mutations in the ABCB4 gene and low biliary 
phospholipid concentration. First described in 2001 by 
Rosmorduc et al. [1], it was later defined as a clinical syn-
drome characterized by at least two of the following cri-
teria [2]: age at onset of biliary symptoms below 40 years, 
intrahepatic echogenic foci or microlithiasis and recur-
rence of biliary symptoms after cholecystectomy. Also, 
most patients report a history of cholesterol gallstones 
amongst their first-degree relatives [2]. Although the 
prevalence of LPAC syndrome remains unknown, it has 
been estimated to account for approximately 5% of cases 
of symptomatic cholelithiasis [3, 4]. The recommended 
medical therapy is ursodeoxycholic acid (UDCA) [5]. In 
the rare cases progressing to end-stage liver disease [2, 6], 
a liver transplant may be indicated.
We present the case of an adult male with prolonged 
jaundice and features consistent with LPAC, in whom 
both ABCB4 and ABCB11 mutations were detected.
Clinical Case
We present the case of a 39-year-old Caucasian male, with no 
relevant medical history, who was admitted in June 2014 for ab-
dominal pain in the periumbilical area associated with nausea, 
with 2 weeks’ duration. In the last 48 h, the patient also noted jaun-
dice and dark urine, with no accompanying changes in his stool. 
His alcohol consumption was low (5 units/week). He reported use 
of protein supplements 1 month before symptom onset, but denied 
recent use of any drugs, teas, or other herbal products. Family his-
tory included gallstone disease in his sister.
On physical examination, he was afebrile and his eyes and skin 
were markedly jaundiced. His abdominal examination was unre-
markable and he showed no stigmata of chronic liver disease.
Laboratory workup included a hemoglobin of 16.0 g/dL, with 
normal white blood cell and platelet count. He had elevated liver 
tests: aspartate aminotransferase (AST) 170, alanine aminotrans-
ferase (ALT) 570, alkaline phosphatase (ALP) 186, and γ-glu-
tamyltransferase (GGT) 699 IU/L; total and direct bilirubin were 
6.65 and 4.95 mg/dL, respectively. There were no changes in kid-
ney function, electrolytes, and coagulation, and C-reactive protein 
(CRP) was 0.3 mg/dL. 
The patient underwent an abdominal ultrasound followed by 
contrast-enhanced computed tomography (Fig. 1), which together 
showed dilated left intrahepatic ducts and common bile duct, 
reaching 7 mm, with no obstructive lesion; no gallstones were de-
tected. Magnetic resonance cholangiopancreatography (MRCP) 
identified a 4-mm stone in the proximal common bile duct, with 
upstream dilation (Fig. 2). Due to a progressive rise in CRP (5.4 
mg/dL), the patient was put on ciprofloxacin assuming cholangitis. 
An endoscopic retrograde cholangiopancreatography (ERCP) was 
then performed, with sphincterotomy, extraction of the common 
bile duct stone with a basket and multiple other smaller stones, 
which were yellow in color. Considering the high risk of stone mi-
gration, a plastic biliary stent was placed to prevent complications 
prior to cholecystectomy.
Despite a progressive decrease in AST, ALT, ALP, and GGT, 
only 24 h after the ERCP there was a marked rise in direct (16 mg/
dL) and total bilirubin (23 mg/dL), which remained elevated for 
several weeks, even after repeated ERCP with removal of addition-
al microlithiases with a basket (Fig. 3). 
An extensive workup was carried out, with exclusion of viral 
hepatitis (hepatitis A, B, and C, Epstein-Barr virus, and cytomega-
lovirus, as well as human immunodeficiency virus), autoimmune 
liver disease (negative antinuclear, anti-smooth muscle, antimito-
chondrial, anti-LKM-1, anti-neutrophil cytoplasmic, anti-gp210 
and anti-Sp100 antibodies, and normal IgG4 level), and metabolic 
diseases including Wilson’s disease (normal serum and urinary 
copper and a slightly diminished ceruloplasmin; no Kayser-
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Fleischer rings), hemochromatosis (elevated ferritin 1,109 ng/mL 
and transferrin saturation 60%, with a normal HFE genotyping), 
α1-antitrypsin deficiency, and porphyria (normal levels of urinary 
and fecal porphyrines and urinary porphobilinogen; normal por-
phobilinogen deaminase activity).
Due to the protracted jaundice with no identifiable cause, a 
liver biopsy was performed. Histology showed hepatic tissue with 
preserved architecture and scarce mixed intralobular and sinusoi-
dal infiltrates, with predominance of mononuclear cells. There was 
focal centrolobular hepatocyte ballooning, focal hepatocellular ne-
crosis (no piecemeal necrosis), and focal regenerative hepatocel-
lular changes resembling rosettes. Mild parenchymal cholestasis 
and hepatocyte siderosis were observed. There was marked deposi-
tion of ceroid pigment in Kupffer cells. No significant fibrosis was 
present. Liver iron content was elevated (2,181 mg/g) and copper 
was within normal range (20.5 mg/g). These aspects were consis-
tent with an acute hepatocellular lesion, with toxic and viral eti-
ologies being more likely.
At this point, the patient was markedly jaundiced, had mild 
tenderness over the right upper quadrant, and complained of nau-
sea, choluria, and pruritus. He showed no signs of hepatic enceph-
alopathy and his coagulation remained normal. Eosinophil count 
was also normal. Having excluded other causes of liver injury, tox-
ic hepatitis was considered to be the most likely explanation for 
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Fig. 1. Contrast-enhanced computed tomography showing mod-
erate dilation of the left intrahepatic bile ducts (arrows). There are 
no changes in liver size or morphology.
Fig. 2. Magnetic resonance cholangiogram showing a 4-mm stone 
in the proximal common bile duct (arrow), with upstream dilation.
Fig. 3. Graphic showing the evolution of 
liver tests (total bilirubin, aspartate amino-
transferase [AST], alanine aminotransfer-
ase [ALT], alkaline phosphatase [ALP], 
γ-glutamyltransferase [GGT]), main clini-
cal landmarks, endoscopic retrograde 
cholangiopancreatographies (ERCP), and 
introduction of ursodeoxycholic acid 
(UDCA).
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maintained jaundice. Drugs used since hospital admission includ-
ed ciprofloxacin, meropenem (both used to treat cholangitis), and 
propofol (used in ERCP). The iodinated contrast agent iobitridol 
was also used during ERCP.
Repeated abdominal ultrasound identified two foci of hepato-
lithiasis in segment II, the largest measuring 11 mm, with upstream 
dilation of the left intrahepatic ducts, with no underlying stricture 
(Fig. 4). Although these had not been identified in MRCP on pre-
sentation, we note that left intrahepatic dilation was already visible 
then.
Considering age below 40 years and hepatolithiasis, as well as 
family history of gallstones in a first-degree relative, the diagnosis 
of LPAC was assumed and the patient was put on UDCA, with 
progressive resolution of symptoms and near normalization of liv-
er enzymes in the following 2 months, allowing for removal of the 
biliary stent. Six weeks after stent removal, there was a new episode 
of abdominal pain due to acute cholangitis (with total bilirubin 7 
mg/dL, CRP 14 mg/dL, and slight common bile duct dilation on 
ultrasound), with good response to treatment with ceftriaxone. He 
was submitted to laparoscopic cholecystectomy 1 month later.
The genetic study of ABCB4 and ABCB11 genes identified the 
mutation c.1954A>G (p.Arg652Gly) in ABCB4 (homozygous) and 
the mutation c.1331T>C (p.Val444Ala) in ABCB11 (heterozy-
gous).
After 3 years of follow-up, the patient is still treated with UDCA 
and maintains surveillance with blood tests and abdominal ultra-
sound every 6 months. He remains asymptomatic, has normal liv-
er tests, and his last ultrasound showed significant reduction of the 
intrahepatic stones (Fig. 5).
Discussion
The ABCB4 gene encodes a P-glycoprotein (MDR3: 
multidrug resistance 3) with flippase activity, responsible 
for the translocation of phosphatidylcholine across the 
canalicular membrane of the hepatocyte [7]. The pro-
posed mechanism in LPAC syndrome is that a defect in 
ABCB4 function reduces the phospholipid content of bile 
and increases the cholesterol saturation [1, 2], thereby in-
creasing its lithogenicity. The reduced formation of mixed 
micelles also results in bile with high concentration of free 
bile salts and hence high detergent properties, leading to 
bile duct membrane injury and cholestasis with increased 
serum GGT levels [2, 5]. 
ABCB4 defects are implicated in a wide spectrum of 
cholestatic diseases besides LPAC [8], including progres-
sive familial intrahepatic cholestasis type 3 (PFIC3) [9], 
benign recurrent intrahepatic cholestasis type 3 (BRIC3) 
[10], intrahepatic cholestasis of pregnancy (ICP) [11, 12], 
drug-induced cholestasis [13], transient neonatal cho-
lestasis [8, 12], and adult “idiopathic” liver fibrosis or cir-
rhosis [12, 14]. Although the relation between genotype 
and phenotype is not always clear, patients with homozy-
gous or compound heterozygous mutations, particularly 
those leading to truncated proteins, tend to have more 
severe disease [8]. Indeed, patients with biallelic ABCB4 
mutations resulting in absence of protein function die 
within the first decade if not transplanted [12], whereas 
patients with milder mutations may be asymptomatic un-
til a trigger such as pregnancy, systemic infection, or a 
xenobiotic reduces MDR3 function below a critical 
threshold [8, 13, 15]. 
Although LPAC syndrome was originally described in 
association with ABCB4 mutations, in a study with 156 
patients who fulfilled the diagnostic criteria, a genetic 
Fig. 5. The reevaluation abdominal ultrasound, performed 3 years 
after the beginning of therapy with ursodeoxycholic acid, showed 
significant reduction of the intrahepatic stones, with the largest 
measuring 5.8 mm (arrow).
Fig. 4. Abdominal ultrasound identified two foci of hepatolithiasis 
in segment II, the largest measuring 11 mm (arrow), with upstream 
dilation of the left intrahepatic ducts
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variant was only found in half of the patients; clinical fea-
tures were similar in the groups with and without these 
variants, suggesting that unexplored regions of the 
ABCB4 gene or different genes could be involved [6]. 
The ABCB11 gene encodes the bile salt export pump 
(BSEP), which transports bile salts across the canalicular 
membrane of the hepatocyte, the limiting step in bile se-
cretion [16]. Mutations in BSEP are linked to PFIC2, 
BRIC2, ICP, and drug-induced liver injury (DILI) [5, 17, 
18]. Two BSEP mutations have also been identified in pa-
tients with primary intrahepatic stones [19], although not 
corresponding to LPAC syndrome. Of note, in contrast 
to most MDR3-related diseases (except for most cases of 
BRIC3 [8]), BSEP-related diseases are characterized by 
normal GGT activity, due to low levels of bile salts in bile 
and consequently less damage do cholangiocytes [18].
We present a case of persistent jaundice in the setting 
of both ABCB4 and ABCB11 mutations, whose interpre-
tation is not straightforward. There is a clear contribution 
of gallstone disease, fulfilling the criteria for LPAC: age of 
presentation below 40 years and hepatolithiasis; this di-
agnosis is further supported by a family history of gall-
stone disease in a first-degree relative and by a favorable 
response to UDCA. 
The persistent jaundice despite retrieval of biliary 
stones raises the possibility that a second mechanism 
might have been involved, namely DILI. Indeed, the 
abrupt increase in total bilirubin occurred 4 days after the 
introduction of ciprofloxacin, which has been described 
as a cause of cholestatic hepatitis with high bilirubin [20]. 
Since the rise in bilirubin happened 24 h after the first 
ERCP, propofol could also be implicated. However, DILI 
is not frequent with such short anesthesia and it is more 
often hepatocellular; also, there was no effect on re-expo-
sure (third ERCP, Fig. 3). To our knowledge, iobitridol 
has no known liver toxicity. Two hypotheses may be con-
sidered: either there was indeed superimposed DILI (to 
which our patient has increased susceptibility, as ex-
plained below), most likely related to ciprofloxacin, or 
there was just a prolonged cholestatic response to the ini-
tial insult (which would be cholangitis due to choledo-
cholithiasis), with bilirubin peaking after the other liver 
enzymes as happens in other types of liver injury. In the 
latter case, this prolonged response could be explained in 
the setting of the gene defects discussed below.
The ABCB4 mutation found in our patient (homozy-
gous Arg652Gly) is a missense mutation that, although 
probably representing a polymorphism [12], has been 
linked to ICP [11] and PFIC3 [8]. It is thought to have 
mild consequences under normal conditions but possibly 
becomes clinically relevant during pregnancy or when 
combined with another mutation [8, 12, 13] (which is the 
case in our patient); however, it has not been linked to 
LPAC. The ABCB11 mutation (heterozygous Val444Ala) 
is a common variation (allele frequencies 50–93%) [21], 
known to cause a 3-fold increase in the risk of DILI [13]; 
it was also implicated in ICP and contraceptive-induced 
cholestasis [22]. This missense mutation probably induc-
es protein misfolding, increasing its degradation [18]. To 
our knowledge, this has also not been associated with 
LPAC. 
The mechanisms involved in the interplay between 
these two mutations and their contribution to our pa-
tient’s evolution are uncertain. Other cases of complex 
interaction between ABCB4 and ABCB11 mutations have 
been described (specifically Val444Ala mutation, as in 
our patient): in a patient with ICP, the combination of 
ABCB4 and homozygous ABCB11 Val444Ala mutations 
was though to explain the severity and early onset of the 
disease; it was speculated that the reduction in MDR3 ex-
pression would modify the phospholipid composition of 
the hepatocyte canalicular membrane, thereby altering 
BSEP expression [23]. In a pair of siblings with MDR3 
mutations and complex cholestatic disorders, the hetero-
zygous Val444Ala mutation was considered to be a dis-
ease modifier [24]. Recently, this ABCB11 mutation was 
also thought to induce decompensation in a patient with 
a mild form of PFIC2 exposed to azithromycin [25].
In summary, we describe the unique case of an adult 
male with acute-onset jaundice (high GGT), with cho-
ledocholithiasis, hepatolithiasis, and persistent conjugat-
ed hyperbilirubinemia after retrieval of stones, fulfilling 
the criteria for LPAC syndrome and with possible super-
imposed DILI, in whom ABCB4 and ABCB11 mutations 
were found, both of which had not been previously de-
scribed in association with LPAC. This case illustrates the 
complexity of the genetics of cholestatic diseases, a field 
of intense research in the last years, where many ques-
tions remain unsolved.
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